Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib hydrochloride for recurrent or persistent uterine cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-27